Pfizer is getting out of the business of developing and marketing HIV medicines by exiting its minority stake in ViiV Healthcare, a company the pharmaceutical giant formed in partnership with GSK 17 years ago.Under a new agreement, Pfizer’s ownership in ViiV will be replaced by Shionogi, another minority shareholder of the HIV company. According to deal terms announced Tuesday, ViiV is canceling Pfizer’s 11.7% stake in the company and Pfizer will receive $1.875 billion. Meanwhile, ViiV will issu...
Continue Reading
Sign up for FREE to read the full article and access 134K+ alternative investment headlines.